A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma Buenos Aires, C1264AAN, Argentina
North Terrace, 5000, Australia
Sofia-Grad, 1431, Bulgaria
Montreal, Quebec H1T 2M4, Canada
Wuhan, 430022, China
Monserrato, 09042, Italy
Fukuoka-ken, 802-0077, Japan
Sapporo Chuo-ku, 064-0919, Japan
Sumida Ku, 130 8575, Japan
Lørenskog, 1478, Norway
Włocławek, 87-800, Poland